董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Mark Iwicki | 男 | Chief Executive Officer and Director | 59 | 3058.60万美元 | 未持股 | 2026-03-16 |
| Amit Munshi | 男 | Director and Chairperson of the Board | 58 | 54.24万美元 | 未持股 | 2026-03-16 |
| Vincent Aurentz | 男 | Director | 58 | 50.05万美元 | 未持股 | 2026-03-16 |
| Dennis Berman | 男 | Director | 75 | 30.64万美元 | 未持股 | 2026-03-16 |
| Arvind Kush | 男 | Director | 43 | 53.73万美元 | 未持股 | 2026-03-16 |
| Arvind Kush | 男 | Director | 43 | 未披露 | 未持股 | 2026-03-16 |
| Roberto Bellini | 男 | Director | 46 | 57.26万美元 | 未持股 | 2026-03-16 |
| Amit Munshi | 男 | Director | 57 | 未披露 | 未持股 | 2026-03-16 |
| David Canner | 男 | Director | 38 | 44.80万美元 | 未持股 | 2026-03-16 |
| Vincent Aurentz | 男 | Director | 58 | 未披露 | 未持股 | 2026-03-16 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Mark Iwicki | 男 | Chief Executive Officer and Director | 59 | 3058.60万美元 | 未持股 | 2026-03-16 |
| David McIntyre | 男 | Chief Financial Officer | 55 | 未披露 | 未持股 | 2026-03-16 |
| Chris Cabell | 男 | Head of Research and Development and President | 57 | 747.53万美元 | 未持股 | 2026-03-16 |
| David McIntyre | 男 | Chief Financial Officer | 55 | 551.97万美元 | 未持股 | 2026-03-16 |
董事简历
中英对照 | 中文 | 英文- Mark Iwicki
-
Mark Iwicki，自2015年9月起担任董事会主席。他曾担任Inhibikase Therapeutics， Inc.（制药公司）的首席执行官（2025年2月以来）。Iwicki先生从2015年9月到2025年2月担任首席执行官，从2017年8月到2021年12月担任总裁，从2015年4月到2015年9月担任董事会执行主席。加入公司之前，他曾担任Civitas Therapeutics， Inc. （Civitas，生物制药公司）的总裁兼首席执行官（2014年1月至2014年11月）。2012年12月至2014年1月，他担任Blend Therapeutics， Inc.（生物制药公司）的总裁兼首席执行官。加入Blend之前，Iwicki先生是Sunovion的总裁兼首席执行官。2007年10月至2012年6月，他在Sepracor Inc./Sunovion任职。加入Sepracor Inc.之前，他曾担任Novartis Pharmaceuticals Corporation（生物制药公司）的副总裁兼业务部门主管。1998年3月至2007年10月，他在诺华公司工作。在此之前，他在Astra Merck Inc.和Merck & Co., Inc.担任管理职务。除了担任Kala Bio， Inc.董事会成员外，他目前还担任Aerovate Therapeutics， Inc., Merus n.v。或Merus（公共临床阶段免疫肿瘤学公司），Akero Therapeutics, Inc., Third Harmonic Bio, Inc.和Q32 Bio Inc.的董事会成员，并曾担任immune Therapeutics， Inc.和Pulmatrix Inc.（所有上市公司）的董事会成员。他持有Ball State大学的工商管理学士学位和Loyola大学的工商管理硕士学位。
Mark Iwicki has served as a member of KALA BIO, Inc. board of directors since September 2015. Mr. Iwicki previoly served as KALA BIO, Inc. President from August 2017 to December 2021 and as Executive Chair of KALA BIO, Inc. board of directors from April 2015 to September 2015. Prior to joining KALA BIO, Inc., Mr. Iwicki served as President and Chief Executive Officer of Civitas Therapeutics, Inc., or Civitas, a biopharmaceutical company, from January 2014 to November 2014. Prior to Civitas, Mr. Iwicki served as President and Chief Executive Officer at Blend Therapeutics, Inc., or Blend, a biopharmaceutical company, from December 2012 to January 2014. Prior to Blend, Mr. Iwicki was President and Chief Executive Officer of Sunovion, a pharmaceutical company. Mr. Iwicki was at Sepracor Inc./Sunovion from October 2007 to June 2012. Prior to joining Sepracor Inc., Mr. Iwicki was Vice President and Biness Unit Head at Novartis Pharmaceuticals Corporation, a biopharmaceutical company. He was at Novartis from March 1998 to October 2007. Prior to that, Mr. Iwicki held management positions at Astra Merck Inc. and Merck & Co., Inc. In addition to serving on KALA BIO, Inc. board of directors, Mr. Iwicki also currently serves on the boards of Aerovate Therapeutics, Inc., Mer, Akero Therapeutics, Inc., Third Harmonic Bio, Inc. and Q32 Bio Inc. and formerly served on the board of Aimmune Therapeutics, Inc. and Pulmatrix Inc., all publicly traded companies. Mr. Iwicki holds a B.S. in Biness Administration from Ball State University and an M.B.A. from Loyola University. - Mark Iwicki，自2015年9月起担任董事会主席。他曾担任Inhibikase Therapeutics， Inc.（制药公司）的首席执行官（2025年2月以来）。Iwicki先生从2015年9月到2025年2月担任首席执行官，从2017年8月到2021年12月担任总裁，从2015年4月到2015年9月担任董事会执行主席。加入公司之前，他曾担任Civitas Therapeutics， Inc. （Civitas，生物制药公司）的总裁兼首席执行官（2014年1月至2014年11月）。2012年12月至2014年1月，他担任Blend Therapeutics， Inc.（生物制药公司）的总裁兼首席执行官。加入Blend之前，Iwicki先生是Sunovion的总裁兼首席执行官。2007年10月至2012年6月，他在Sepracor Inc./Sunovion任职。加入Sepracor Inc.之前，他曾担任Novartis Pharmaceuticals Corporation（生物制药公司）的副总裁兼业务部门主管。1998年3月至2007年10月，他在诺华公司工作。在此之前，他在Astra Merck Inc.和Merck & Co., Inc.担任管理职务。除了担任Kala Bio， Inc.董事会成员外，他目前还担任Aerovate Therapeutics， Inc., Merus n.v。或Merus（公共临床阶段免疫肿瘤学公司），Akero Therapeutics, Inc., Third Harmonic Bio, Inc.和Q32 Bio Inc.的董事会成员，并曾担任immune Therapeutics， Inc.和Pulmatrix Inc.（所有上市公司）的董事会成员。他持有Ball State大学的工商管理学士学位和Loyola大学的工商管理硕士学位。
- Mark Iwicki has served as a member of KALA BIO, Inc. board of directors since September 2015. Mr. Iwicki previoly served as KALA BIO, Inc. President from August 2017 to December 2021 and as Executive Chair of KALA BIO, Inc. board of directors from April 2015 to September 2015. Prior to joining KALA BIO, Inc., Mr. Iwicki served as President and Chief Executive Officer of Civitas Therapeutics, Inc., or Civitas, a biopharmaceutical company, from January 2014 to November 2014. Prior to Civitas, Mr. Iwicki served as President and Chief Executive Officer at Blend Therapeutics, Inc., or Blend, a biopharmaceutical company, from December 2012 to January 2014. Prior to Blend, Mr. Iwicki was President and Chief Executive Officer of Sunovion, a pharmaceutical company. Mr. Iwicki was at Sepracor Inc./Sunovion from October 2007 to June 2012. Prior to joining Sepracor Inc., Mr. Iwicki was Vice President and Biness Unit Head at Novartis Pharmaceuticals Corporation, a biopharmaceutical company. He was at Novartis from March 1998 to October 2007. Prior to that, Mr. Iwicki held management positions at Astra Merck Inc. and Merck & Co., Inc. In addition to serving on KALA BIO, Inc. board of directors, Mr. Iwicki also currently serves on the boards of Aerovate Therapeutics, Inc., Mer, Akero Therapeutics, Inc., Third Harmonic Bio, Inc. and Q32 Bio Inc. and formerly served on the board of Aimmune Therapeutics, Inc. and Pulmatrix Inc., all publicly traded companies. Mr. Iwicki holds a B.S. in Biness Administration from Ball State University and an M.B.A. from Loyola University.
- Amit Munshi
-
Amit Munshi，自2014年7月15日合并完成之时起，担任本公司的总裁、首席执行官、董事；此前，从2012年5月起，担任Private Epirus的总裁、首席执行官、董事。2011年，他担任Percivia LLC的首席执行官；2005年8月至2010年12月，还是上市公司Kythera Biopharmaceuticals, Inc.的共同创始人、首席业务官。此前，他在Amgen Inc.担任过多个领导职务，其中包括肾脏病欧洲地区总经理。他在美国及国际地区拥有超过24年的制药和生物技术经验，涉及综合管理、产品开发、授权、业务开发。他现为多个私营公司的董事： Oxeia Biopharmaceuticals, Inc.、Adrista, Inc. 、Cytrellis Biosystems, Inc.；2005-2010，担任Nephrian, Inc.的董事；2012-2014，担任私营公司Cynvenio Biosystems, Inc.的董事。
Amit Munshi has served as President, Chief Executive Officer and a director of the Company since the Merger closed in July 2014 and prior to that time served as President and Chief Executive Officer and a director of Private Epirus beginning in May 2012. Mr. Munshi served as Chief Executive Officer of Percivia LLC in 2011 and also was a co-founder, and the chief business officer, at Kythera Biopharmaceuticals, Inc. acquired by Allegran Plc, a publicly traded company, from August 2005 until December 2010. Previously, he held leadership positions at Amgen Inc., including General Manager, Nephrology Europe. Mr. Munshi serves on the boards of Oxeia Biopharmaceuticals, Inc., of which he was a co-founder and executive officer, Adrista, Inc. and Cytrellis Biosystems, Inc., all of which are privately held companies, and previously served on the boards of Nephrian, Inc., a privately held company, from 2005 until 2010 and Cynvenio Biosystems, Inc., a privately held company, from 2012 until 2014. Mr. Munshi serves on the compensation committee of Oxeia Biopharmaceuticals. - Amit Munshi，自2014年7月15日合并完成之时起，担任本公司的总裁、首席执行官、董事；此前，从2012年5月起，担任Private Epirus的总裁、首席执行官、董事。2011年，他担任Percivia LLC的首席执行官；2005年8月至2010年12月，还是上市公司Kythera Biopharmaceuticals, Inc.的共同创始人、首席业务官。此前，他在Amgen Inc.担任过多个领导职务，其中包括肾脏病欧洲地区总经理。他在美国及国际地区拥有超过24年的制药和生物技术经验，涉及综合管理、产品开发、授权、业务开发。他现为多个私营公司的董事： Oxeia Biopharmaceuticals, Inc.、Adrista, Inc. 、Cytrellis Biosystems, Inc.；2005-2010，担任Nephrian, Inc.的董事；2012-2014，担任私营公司Cynvenio Biosystems, Inc.的董事。
- Amit Munshi has served as President, Chief Executive Officer and a director of the Company since the Merger closed in July 2014 and prior to that time served as President and Chief Executive Officer and a director of Private Epirus beginning in May 2012. Mr. Munshi served as Chief Executive Officer of Percivia LLC in 2011 and also was a co-founder, and the chief business officer, at Kythera Biopharmaceuticals, Inc. acquired by Allegran Plc, a publicly traded company, from August 2005 until December 2010. Previously, he held leadership positions at Amgen Inc., including General Manager, Nephrology Europe. Mr. Munshi serves on the boards of Oxeia Biopharmaceuticals, Inc., of which he was a co-founder and executive officer, Adrista, Inc. and Cytrellis Biosystems, Inc., all of which are privately held companies, and previously served on the boards of Nephrian, Inc., a privately held company, from 2005 until 2010 and Cynvenio Biosystems, Inc., a privately held company, from 2012 until 2014. Mr. Munshi serves on the compensation committee of Oxeia Biopharmaceuticals.
- Vincent Aurentz
-
Vincent Aurentz，自2016年8月起担任Arena Pharmaceuticals, Inc.的执行副总裁兼首席业务官。此前，他曾担任Epirus biopharmacpharmaceuticals, Inc.的首席商务官（2015年11月至2016年7月）。加入Epirus之前，他曾担任HemoShear Therapeutics, LLC的总裁（从2013年7月到2015年11月），负责科学研究和业务发展工作，包括与辉瑞公司（Pfizer Inc.）、礼来公司（Eli Lilly）、詹森研发公司（Janssen R&D）和儿童国家健康系统（Children’s National Health System）等全球组织的合作。从2015年11月起担任Zalicus Inc.高级副总裁、首席商务官。2013年7月-2015年11月，担任HemoShear Therapeutics总裁，监管科学和业务发展事务，包括与全球机构的合作如Pfizer, Eli Lilly, Janssen R&D和Children’s National Health System。此前，2012年7月-2013年12月，担任Merck KGaA Merck Serono的执行副总裁和执行管理委员会成员，领导研发项目、投资组合战略以及领导所有的交易活动和风投。2010年10月-2012年4月，在Quintiles担任执行副总裁，是一家风险资本和顾问公司的联合创始人和总经理；在Andersen Consulting （现为 Accenture）开始他的职业生涯。他获得Villanova University的数学学士学位。
Vincent Aurentz has served as our Senior Vice President and Chief Business Officer since November 2015. He was formerly the President of HemoShear Therapeutics, from July 2013 to November 2015 where he oversaw the scientific and business development efforts including collaborations with global organizations such as Pfizer, Eli Lilly, Janssen R&D and Children's National Health System. Prior to joining HemoShear Therapeutics, Mr. Aurentz was Executive Vice President and member of the Executive Management Board at Merck KGaA Merck Serono, from July 2012 to December 2013 where he directed R&D programs, portfolio strategy and headed all deal activity and venture investments. He is a former Executive Vice President at Quintiles, where he served from October 2010 to April 2012 Co-founder and Managing Director of a venture capital and advisory business and started his career at Andersen Consulting (now Accenture). - Vincent Aurentz，自2016年8月起担任Arena Pharmaceuticals, Inc.的执行副总裁兼首席业务官。此前，他曾担任Epirus biopharmacpharmaceuticals, Inc.的首席商务官（2015年11月至2016年7月）。加入Epirus之前，他曾担任HemoShear Therapeutics, LLC的总裁（从2013年7月到2015年11月），负责科学研究和业务发展工作，包括与辉瑞公司（Pfizer Inc.）、礼来公司（Eli Lilly）、詹森研发公司（Janssen R&D）和儿童国家健康系统（Children’s National Health System）等全球组织的合作。从2015年11月起担任Zalicus Inc.高级副总裁、首席商务官。2013年7月-2015年11月，担任HemoShear Therapeutics总裁，监管科学和业务发展事务，包括与全球机构的合作如Pfizer, Eli Lilly, Janssen R&D和Children’s National Health System。此前，2012年7月-2013年12月，担任Merck KGaA Merck Serono的执行副总裁和执行管理委员会成员，领导研发项目、投资组合战略以及领导所有的交易活动和风投。2010年10月-2012年4月，在Quintiles担任执行副总裁，是一家风险资本和顾问公司的联合创始人和总经理；在Andersen Consulting （现为 Accenture）开始他的职业生涯。他获得Villanova University的数学学士学位。
- Vincent Aurentz has served as our Senior Vice President and Chief Business Officer since November 2015. He was formerly the President of HemoShear Therapeutics, from July 2013 to November 2015 where he oversaw the scientific and business development efforts including collaborations with global organizations such as Pfizer, Eli Lilly, Janssen R&D and Children's National Health System. Prior to joining HemoShear Therapeutics, Mr. Aurentz was Executive Vice President and member of the Executive Management Board at Merck KGaA Merck Serono, from July 2012 to December 2013 where he directed R&D programs, portfolio strategy and headed all deal activity and venture investments. He is a former Executive Vice President at Quintiles, where he served from October 2010 to April 2012 Co-founder and Managing Director of a venture capital and advisory business and started his career at Andersen Consulting (now Accenture).
- Dennis Berman
-
Dennis Berman一直担任许多私人生物技术和科技公司的联合创始人、董事会成员和/或种子投资者，其中5家公司已经上市。自2017年6月以来，Berman先生一直担任董事会咨询和风险投资公司Molino Ventures，LLC的总裁。2008年5月至2017年4月，他担任Tocagen Inc.（一家公开上市的基因治疗公司，利用逆转录病毒和前体药物激活患者的癌症免疫系统）企业发展的联合创始人兼执行Vice President。他还于2007年8月至2017年4月担任Tocagen Inc.的董事会成员。Berman先生曾担任种子投资者，联合创始人和/或董事会成员的其他上市公司包括首批软件即服务公司之一Intervu，在线筹款先锋Kintera Inc.，专注于嘌呤/嘧啶代谢化合物的公司Gensia和美国第一家基因治疗公司Viagene，它利用了一种不可复制的逆转录病毒。Berman先生也是水处理公司Calabrian的种子投资者。此前，Berman先生是几家大型律师事务所的公司法合伙人，包括Reavis&McGrath现在的Norton Rose Fulbright和Sonnenschein Nath&Rosenthal（现在的Dentons）。Berman先生拥有宾夕法尼亚大学沃顿商学院（Wharton School of the University of Pennsylvania）会计/经济学学士学位，宾夕法尼亚大学（University of Pennsylvania）经济学学士学位和哈佛大学法学院（Harvard Law School）法学博士学位。他一直是哈佛大学创新实验室（i-lab）的常驻企业家，也是哈佛大学公共卫生学院（the Harvard School of Public Health）的客座演讲人。
Dennis Berman has served as a member of Board of Directors since December 2020. Currently, Mr. Berman is President of Molino Ventures, a board advisory and venture capital firm, since June 2017. Previoly, he was Co founder and Executive Vice President of Corporate Development of Tocagen Inc., a then publicly traded gene therapy company, from July 2007 to April 2017. Other public companies for which Mr. Berman has served as a seed investor, co founder, and/or board member include InterVu Inc., one of the first software as a service companies, which was acquired by Akamai; Kintera Inc., an online fundraising pioneer, which was acquired by Blackbaud; Gensia Pharmaceuticals, Inc., foced on purine/pyrimidine metabolism compounds, which was acquired by Teva (NASDAQ: TEVE); and Viagene Therapeutics Inc., a U.S. gene therapy company, which was acquired by Chiron/Novartis (NYSE: NVS). In addition, he was co founder of Genovo, a private gene therapy company. Mr. Berman also was a seed investor in Calabrian, a private water treatment company, which was acquired by SK Capital. Earlier, Mr. Berman was a corporate law partner at several large law firms, including Sonnenschein Nath & Rosenthal, now Dentons, and Reavis & McGrath, now Norton Rose Fulbright. Mr. Berman holds a Bachelor of Science from the Wharton School of the University of Pennsylvania in Accounting/ Economics, a Bachelor of Arts from the University of Pennsylvania in Economics and is a graduate of Harvard Law School. He has been an Entrepreneur in Residence at Harvard's Innovation Lab (i lab) and a guest speaker at Harvard School of Public Health. - Dennis Berman一直担任许多私人生物技术和科技公司的联合创始人、董事会成员和/或种子投资者，其中5家公司已经上市。自2017年6月以来，Berman先生一直担任董事会咨询和风险投资公司Molino Ventures，LLC的总裁。2008年5月至2017年4月，他担任Tocagen Inc.（一家公开上市的基因治疗公司，利用逆转录病毒和前体药物激活患者的癌症免疫系统）企业发展的联合创始人兼执行Vice President。他还于2007年8月至2017年4月担任Tocagen Inc.的董事会成员。Berman先生曾担任种子投资者，联合创始人和/或董事会成员的其他上市公司包括首批软件即服务公司之一Intervu，在线筹款先锋Kintera Inc.，专注于嘌呤/嘧啶代谢化合物的公司Gensia和美国第一家基因治疗公司Viagene，它利用了一种不可复制的逆转录病毒。Berman先生也是水处理公司Calabrian的种子投资者。此前，Berman先生是几家大型律师事务所的公司法合伙人，包括Reavis&McGrath现在的Norton Rose Fulbright和Sonnenschein Nath&Rosenthal（现在的Dentons）。Berman先生拥有宾夕法尼亚大学沃顿商学院（Wharton School of the University of Pennsylvania）会计/经济学学士学位，宾夕法尼亚大学（University of Pennsylvania）经济学学士学位和哈佛大学法学院（Harvard Law School）法学博士学位。他一直是哈佛大学创新实验室（i-lab）的常驻企业家，也是哈佛大学公共卫生学院（the Harvard School of Public Health）的客座演讲人。
- Dennis Berman has served as a member of Board of Directors since December 2020. Currently, Mr. Berman is President of Molino Ventures, a board advisory and venture capital firm, since June 2017. Previoly, he was Co founder and Executive Vice President of Corporate Development of Tocagen Inc., a then publicly traded gene therapy company, from July 2007 to April 2017. Other public companies for which Mr. Berman has served as a seed investor, co founder, and/or board member include InterVu Inc., one of the first software as a service companies, which was acquired by Akamai; Kintera Inc., an online fundraising pioneer, which was acquired by Blackbaud; Gensia Pharmaceuticals, Inc., foced on purine/pyrimidine metabolism compounds, which was acquired by Teva (NASDAQ: TEVE); and Viagene Therapeutics Inc., a U.S. gene therapy company, which was acquired by Chiron/Novartis (NYSE: NVS). In addition, he was co founder of Genovo, a private gene therapy company. Mr. Berman also was a seed investor in Calabrian, a private water treatment company, which was acquired by SK Capital. Earlier, Mr. Berman was a corporate law partner at several large law firms, including Sonnenschein Nath & Rosenthal, now Dentons, and Reavis & McGrath, now Norton Rose Fulbright. Mr. Berman holds a Bachelor of Science from the Wharton School of the University of Pennsylvania in Accounting/ Economics, a Bachelor of Arts from the University of Pennsylvania in Economics and is a graduate of Harvard Law School. He has been an Entrepreneur in Residence at Harvard's Innovation Lab (i lab) and a guest speaker at Harvard School of Public Health.
- Arvind Kush
-
Arvind Kush，自2021年11月起担任Rayzebio公司首席财务官。此前，库什曾于2018年2月至2021年11月担任美银证券全球企业投资银行部医疗集团董事总经理，就战略和融资交易为生物制药公司提供咨询。从2008年7月到2018年1月，库什在美银证券及其前身公司的医疗保健投资银行团队担任越来越多的职务，最近担任董事。2004年1月至2006年6月，库什先生在Caritor India Pvt. Ltd.（现为NTT Data Services）担任高级软件工程师。库什在印度维斯维斯瓦拉亚理工大学获得计算机科学学士学位，在埃默里大学戈伊苏埃塔商学院获得工商管理硕士学位。
Arvind Kush,has served as Rayzebio, Inc. Chief Financial Officer since November 2021. Previously, Mr. Kush served as managing director in the Healthcare Group in the Global Corporate Investment Banking Division at BofA Securities from February 2018 until November 2021, advising biopharmaceutical companies on strategic and financing transactions. From July 2008 until January 2018, Mr. Kush served in roles of increasing responsibilities in the healthcare investment banking team at BofA Securities and its predecessor companies,serving most recently as director. From January 2004 until June 2006, Mr. Kush served as senior software engineer at Caritor India Pvt. Ltd. (now NTT Data Services). Mr. Kush earned a B.E. in computer science from Visvesvaraya Technological University, India, and an M.B.A. from the Goizueta Business School at Emory University. - Arvind Kush，自2021年11月起担任Rayzebio公司首席财务官。此前，库什曾于2018年2月至2021年11月担任美银证券全球企业投资银行部医疗集团董事总经理，就战略和融资交易为生物制药公司提供咨询。从2008年7月到2018年1月，库什在美银证券及其前身公司的医疗保健投资银行团队担任越来越多的职务，最近担任董事。2004年1月至2006年6月，库什先生在Caritor India Pvt. Ltd.（现为NTT Data Services）担任高级软件工程师。库什在印度维斯维斯瓦拉亚理工大学获得计算机科学学士学位，在埃默里大学戈伊苏埃塔商学院获得工商管理硕士学位。
- Arvind Kush,has served as Rayzebio, Inc. Chief Financial Officer since November 2021. Previously, Mr. Kush served as managing director in the Healthcare Group in the Global Corporate Investment Banking Division at BofA Securities from February 2018 until November 2021, advising biopharmaceutical companies on strategic and financing transactions. From July 2008 until January 2018, Mr. Kush served in roles of increasing responsibilities in the healthcare investment banking team at BofA Securities and its predecessor companies,serving most recently as director. From January 2004 until June 2006, Mr. Kush served as senior software engineer at Caritor India Pvt. Ltd. (now NTT Data Services). Mr. Kush earned a B.E. in computer science from Visvesvaraya Technological University, India, and an M.B.A. from the Goizueta Business School at Emory University.
- Arvind Kush
-
Arvind KH自2024年10月起担任董事会成员。KH先生自2024年7月起担任生物技术公司Candid Therapeutics，Inc.（“Candid”）的首席财务和首席财务官。在加入Candid之前，KH先生于2021年11月在生物技术公司RayzeBio，Inc.担任首席财务官，直至2024年2月被Bristol Myers Squibb收购。Previoly，KH先生担任越来越多的职责，最近于2018年2月至2021年11月在美国银行证券全球企业投资银行部门担任医疗保健集团董事总经理，就战略和融资交易为生物制药公司提供建议。KH先生拥有Visvesvaraya理工大学计算机科学工程学士学位和埃默里大学Goizueta Biness School MBA学位。
Arvind Kh has served as a member of Board of Directors since October 2024. Mr. Kh has served as Chief Financial and Chief Biness Officer of Candid Therapeutics, Inc. ("Candid"), a biotechnology company, since July 2024. Prior to Candid, Mr. Kh was Chief Financial Officer at RayzeBio, Inc., a biotechnology company, from November 2021 until its acquisition by Bristol Myers Squibb in February 2024. Previoly, Mr. Kh served in roles of increasing responsibility, most recently as managing director in the Healthcare Group in the Global Corporate Investment Banking Division at BofA Securities from February 2018 until November 2021, advising biopharmaceutical companies on strategic and financing transactions. Mr. Kh holds a Bachelor of Engineering in Computer Science from Visvesvaraya Technological University and an MBA from Goizueta Biness School, Emory University. - Arvind KH自2024年10月起担任董事会成员。KH先生自2024年7月起担任生物技术公司Candid Therapeutics，Inc.（“Candid”）的首席财务和首席财务官。在加入Candid之前，KH先生于2021年11月在生物技术公司RayzeBio，Inc.担任首席财务官，直至2024年2月被Bristol Myers Squibb收购。Previoly，KH先生担任越来越多的职责，最近于2018年2月至2021年11月在美国银行证券全球企业投资银行部门担任医疗保健集团董事总经理，就战略和融资交易为生物制药公司提供建议。KH先生拥有Visvesvaraya理工大学计算机科学工程学士学位和埃默里大学Goizueta Biness School MBA学位。
- Arvind Kh has served as a member of Board of Directors since October 2024. Mr. Kh has served as Chief Financial and Chief Biness Officer of Candid Therapeutics, Inc. ("Candid"), a biotechnology company, since July 2024. Prior to Candid, Mr. Kh was Chief Financial Officer at RayzeBio, Inc., a biotechnology company, from November 2021 until its acquisition by Bristol Myers Squibb in February 2024. Previoly, Mr. Kh served in roles of increasing responsibility, most recently as managing director in the Healthcare Group in the Global Corporate Investment Banking Division at BofA Securities from February 2018 until November 2021, advising biopharmaceutical companies on strategic and financing transactions. Mr. Kh holds a Bachelor of Engineering in Computer Science from Visvesvaraya Technological University and an MBA from Goizueta Biness School, Emory University.
- Roberto Bellini
-
Roberto Bellini自2024年10月起担任董事会成员。Bellini先生目前担任家族办公室生物技术基金BSQUARED Capital Inc.的管理合伙人，自2023年起。自2016年5月起，他还担任生物技术工业协会BIOTECanada的董事，目前担任执行委员会成员，previoly于2016年5月和2019年6月以及2021年7月和2024年7月担任副主席。Bellini先生曾于2010年1月和2023年7月担任晚期生物制药公司BELL Health的总裁兼首席执行官和董事。在他的领导下，BELL Health开发了camlipixant，这是一种从临床前到3期的慢性咳嗽的P2X3拮抗剂。BELL Health随后于2023年被GSK PLC收购。Bellini先生拥有麦吉尔大学生物化学理学学士学位。
Roberto Bellini has served as a member of Board of Directors since October 2024. Mr. Bellini currently serves as a Managing Partner at BSQUARED Capital Inc., a family office biotech fund, since 2023. He has also served as a director of BIOTECanada, a biotechnology industry association, since May 2016, where he is currently a member of the Executive Committee and previoly served as Vice Chair from May 2016 and June 2019 and from July 2021 and July 2024. Mr. Bellini served as President and Chief Executive Officer and a director of BELL Health, a late stage biopharmaceutical company, beten January 2010 and July 2023. Under his leadership, BELL Health developed camlipixant, a P2X3 antagonist for chronic cough from preclinical to Phase 3. BELL Health was subsequently acquired by GSK plc in 2023. Mr. Bellini holds a Bachelor of Science in Biochemistry from McGill University. - Roberto Bellini自2024年10月起担任董事会成员。Bellini先生目前担任家族办公室生物技术基金BSQUARED Capital Inc.的管理合伙人，自2023年起。自2016年5月起，他还担任生物技术工业协会BIOTECanada的董事，目前担任执行委员会成员，previoly于2016年5月和2019年6月以及2021年7月和2024年7月担任副主席。Bellini先生曾于2010年1月和2023年7月担任晚期生物制药公司BELL Health的总裁兼首席执行官和董事。在他的领导下，BELL Health开发了camlipixant，这是一种从临床前到3期的慢性咳嗽的P2X3拮抗剂。BELL Health随后于2023年被GSK PLC收购。Bellini先生拥有麦吉尔大学生物化学理学学士学位。
- Roberto Bellini has served as a member of Board of Directors since October 2024. Mr. Bellini currently serves as a Managing Partner at BSQUARED Capital Inc., a family office biotech fund, since 2023. He has also served as a director of BIOTECanada, a biotechnology industry association, since May 2016, where he is currently a member of the Executive Committee and previoly served as Vice Chair from May 2016 and June 2019 and from July 2021 and July 2024. Mr. Bellini served as President and Chief Executive Officer and a director of BELL Health, a late stage biopharmaceutical company, beten January 2010 and July 2023. Under his leadership, BELL Health developed camlipixant, a P2X3 antagonist for chronic cough from preclinical to Phase 3. BELL Health was subsequently acquired by GSK plc in 2023. Mr. Bellini holds a Bachelor of Science in Biochemistry from McGill University.
- Amit Munshi
-
Amit Munshi自2024年10月起担任董事会成员。Munshi先生于2024年5月至2025年4月期间担任生物技术公司Orna Therapeutics，Inc.（“Orna”）的总裁、首席执行官和董事会成员。在此之前，Munshi先生曾于2023年5月担任RNA疗法公司ReNAGade Therapeutics，Inc.的总裁、首席执行官和董事会成员，直至2024年5月被Orna收购。Munshi先生还自2023年3月起担任上市生物技术公司Zura Bio Limited（“Zura”）（纳斯达克股票代码：ZURA）的董事会主席，并自2022年11月起担任Zura会计前身的董事和董事会主席。Munshi先生自2020年5月起担任上市临床阶段生物技术公司Galecto Inc.（NASDAQ：GLTO）的董事会成员和审计委员会成员，自2020年1月起担任药物发现公司Enterprise Therapeutics的董事会主席，自2025年4月起担任基因和细胞治疗公司Sensorion（EPA：ALSEN）的董事会主席，并自2026年2月起担任临时首席执行官。Munshi先生于2016年5月至2022年3月期间担任阿里那制药公司（一家当时上市的生物制药公司）的总裁兼首席执行官，并于2016年6月至2022年3月期间担任该公司的董事会成员，直至2022年3月该公司被辉瑞收购。Munshi先生还于2017年6月至2021年3月期间担任公开上市的临床阶段生物制药公司Pulmatrix Inc.（纳斯达克股票代码：PULM）的董事会成员和审计委员会成员。Previoly，从2012年5月到2016年5月，Munshi先生是Epir Biopharmaceuticals的首席执行官，该公司于2016年7月25日申请破产。在加入Epir之前，Munshi先生是Percivia LLC（后被强生收购）的首席执行官，以及Kythera生物制药Inc.（后被艾尔建收购）的首席BINCE官和联合创始人。Munshi先生拥有加州大学河滨分校的经济学学士学位和历史学学士学位，以及克莱蒙特研究生大学Peter F. Drucker管理学院的工商管理硕士学位。
Amit Munshi has served as a member of Board of Directors since October 2024. Mr. Munshi served as the President, Chief Executive Officer and as a board member of Orna Therapeutics, Inc. ("Orna"), a biotechnology company, from May 2024 to April 2025. Prior to this, Mr. Munshi served as the President, Chief Executive Officer and as a board member of ReNAgade Therapeutics, Inc., an RNA therapeutics company, from May 2023 until its acquisition by Orna in May 2024. Mr. Munshi also has served as chairman of the board of directors of Zura Bio Limited ("Zura") (NASDAQ: ZURA), a publicly traded biotechnology company, since March 2023, and as a director and the chairman of the board of directors of Zura's accounting predecessor since November 2022. Mr. Munshi has served as a member of the board of directors and audit committee of Galecto Inc. (NASDAQ: GLTO), a publicly traded clinical stage biotechnology company, since May 2020, as the chairman of the board of Enterprise Therapeutics, a drug discovery company, since January 2020, and as chairman of the board of Sensorion (EPA: ALSEN), a gene and cell therapy company, since April 2025, where he has also served as interim CEO since February 2026. Mr. Munshi was President and Chief Executive Officer of Arena Pharmaceuticals Inc., a then publicly traded biopharmaceutical company, from May 2016 to March 2022 and a member of its board of directors from June 2016 until its acquisition by Pfizer in March 2022. Mr. Munshi also served as a member of the board of directors and audit committee of Pulmatrix Inc. (NASDAQ: PULM), a publicly traded clinical stage biopharmaceutical company, from June 2017 until March 2021. Previoly, from May 2012 until May 2016, Mr. Munshi was the Chief Executive Officer of Epir Biopharmaceuticals, which filed for bankruptcy on July 25, 2016. Prior to Epir, Mr. Munshi was Chief Executive Officer of Percivia LLC, which was later acquired by Johnson & Johnson, and Chief Biness Officer and co founder of Kythera Biopharmaceuticals Inc., which was subsequently acquired by Allergan. Mr. Munshi holds a B.S. in Economics and a B.A. in History from the University of California, Riverside, and an M.B.A. from the Peter F. Drucker School of Management at Claremont Graduate University. - Amit Munshi自2024年10月起担任董事会成员。Munshi先生于2024年5月至2025年4月期间担任生物技术公司Orna Therapeutics，Inc.（“Orna”）的总裁、首席执行官和董事会成员。在此之前，Munshi先生曾于2023年5月担任RNA疗法公司ReNAGade Therapeutics，Inc.的总裁、首席执行官和董事会成员，直至2024年5月被Orna收购。Munshi先生还自2023年3月起担任上市生物技术公司Zura Bio Limited（“Zura”）（纳斯达克股票代码：ZURA）的董事会主席，并自2022年11月起担任Zura会计前身的董事和董事会主席。Munshi先生自2020年5月起担任上市临床阶段生物技术公司Galecto Inc.（NASDAQ：GLTO）的董事会成员和审计委员会成员，自2020年1月起担任药物发现公司Enterprise Therapeutics的董事会主席，自2025年4月起担任基因和细胞治疗公司Sensorion（EPA：ALSEN）的董事会主席，并自2026年2月起担任临时首席执行官。Munshi先生于2016年5月至2022年3月期间担任阿里那制药公司（一家当时上市的生物制药公司）的总裁兼首席执行官，并于2016年6月至2022年3月期间担任该公司的董事会成员，直至2022年3月该公司被辉瑞收购。Munshi先生还于2017年6月至2021年3月期间担任公开上市的临床阶段生物制药公司Pulmatrix Inc.（纳斯达克股票代码：PULM）的董事会成员和审计委员会成员。Previoly，从2012年5月到2016年5月，Munshi先生是Epir Biopharmaceuticals的首席执行官，该公司于2016年7月25日申请破产。在加入Epir之前，Munshi先生是Percivia LLC（后被强生收购）的首席执行官，以及Kythera生物制药Inc.（后被艾尔建收购）的首席BINCE官和联合创始人。Munshi先生拥有加州大学河滨分校的经济学学士学位和历史学学士学位，以及克莱蒙特研究生大学Peter F. Drucker管理学院的工商管理硕士学位。
- Amit Munshi has served as a member of Board of Directors since October 2024. Mr. Munshi served as the President, Chief Executive Officer and as a board member of Orna Therapeutics, Inc. ("Orna"), a biotechnology company, from May 2024 to April 2025. Prior to this, Mr. Munshi served as the President, Chief Executive Officer and as a board member of ReNAgade Therapeutics, Inc., an RNA therapeutics company, from May 2023 until its acquisition by Orna in May 2024. Mr. Munshi also has served as chairman of the board of directors of Zura Bio Limited ("Zura") (NASDAQ: ZURA), a publicly traded biotechnology company, since March 2023, and as a director and the chairman of the board of directors of Zura's accounting predecessor since November 2022. Mr. Munshi has served as a member of the board of directors and audit committee of Galecto Inc. (NASDAQ: GLTO), a publicly traded clinical stage biotechnology company, since May 2020, as the chairman of the board of Enterprise Therapeutics, a drug discovery company, since January 2020, and as chairman of the board of Sensorion (EPA: ALSEN), a gene and cell therapy company, since April 2025, where he has also served as interim CEO since February 2026. Mr. Munshi was President and Chief Executive Officer of Arena Pharmaceuticals Inc., a then publicly traded biopharmaceutical company, from May 2016 to March 2022 and a member of its board of directors from June 2016 until its acquisition by Pfizer in March 2022. Mr. Munshi also served as a member of the board of directors and audit committee of Pulmatrix Inc. (NASDAQ: PULM), a publicly traded clinical stage biopharmaceutical company, from June 2017 until March 2021. Previoly, from May 2012 until May 2016, Mr. Munshi was the Chief Executive Officer of Epir Biopharmaceuticals, which filed for bankruptcy on July 25, 2016. Prior to Epir, Mr. Munshi was Chief Executive Officer of Percivia LLC, which was later acquired by Johnson & Johnson, and Chief Biness Officer and co founder of Kythera Biopharmaceuticals Inc., which was subsequently acquired by Allergan. Mr. Munshi holds a B.S. in Economics and a B.A. in History from the University of California, Riverside, and an M.B.A. from the Peter F. Drucker School of Management at Claremont Graduate University.
- David Canner
-
David Canner自2024年10月起担任董事会成员。Canner博士是医疗保健投资公司Sole Capital的合伙人，他于2018年加入该公司。Canner博士过去八年一直担任生物技术公司的投资者，并在治疗和下一代诊断领域的私营生命科学公司的董事会任职。Canner博士拥有普林斯顿大学化学学士学位和麻省理工学院生物学博士学位。
David Canner has served as a member of Board of Directors since October 2024. Dr. Canner is a partner at Sole Capital, a healthcare investment firm, which he joined in 2018. Dr. Canner has served as an investor in biotechnology companies for the past eight years and has served on the board of directors of privately held life sciences companies in therapeutics and next generation diagnostics. Dr. Canner holds a B.A. in Chemistry from Princeton University and a Ph.D. in Biology from the Massachetts Institute of Technology. - David Canner自2024年10月起担任董事会成员。Canner博士是医疗保健投资公司Sole Capital的合伙人，他于2018年加入该公司。Canner博士过去八年一直担任生物技术公司的投资者，并在治疗和下一代诊断领域的私营生命科学公司的董事会任职。Canner博士拥有普林斯顿大学化学学士学位和麻省理工学院生物学博士学位。
- David Canner has served as a member of Board of Directors since October 2024. Dr. Canner is a partner at Sole Capital, a healthcare investment firm, which he joined in 2018. Dr. Canner has served as an investor in biotechnology companies for the past eight years and has served on the board of directors of privately held life sciences companies in therapeutics and next generation diagnostics. Dr. Canner holds a B.A. in Chemistry from Princeton University and a Ph.D. in Biology from the Massachetts Institute of Technology.
- Vincent Aurentz
-
Vincent Aurentz自2025年2月起担任董事会成员。Aurentz先生目前自2024年12月起担任Forward Therapeutics，Inc.的董事会成员，Forward Therapeutics，Inc.是一家私营生物制药公司，并于2020年10月至2024年12月被Lundbeck A/S收购之前，曾是当时上市的临床阶段生物制药公司Longboard Pharmaceuticals, Inc.的董事会成员。Previoly，他于2016年8月在Arena Pharmaceuticals, Inc.担任执行副总裁兼首席BINCE官，该公司当时是一家上市的生物制药公司，直到2022年3月被辉瑞收购。Aurentz先生是Epir Biopharmaceuticals，Inc.的首席BINCE官，曾担任HemoShear Therapeutics，LLC的总裁和董事会成员。在此之前，Aurentz先生曾在默沙东 KGaA工作了近十年，担任过多个专注于企业发展和战略的行政领导职务，包括在默沙东 KGaA（默沙东 Serono S.A.）（XETR：MRK）担任执行副总裁兼执行管理委员会成员，在那里他指导了所有研发计划、投资组合战略并领导了包括风险投资在内的所有交易活动。Aurentz先生是昆泰公司的前执行副总裁，也是一家专注于生命科学的风险投资和咨询机构的联合创始人/董事总经理。在安德森咨询公司（现埃森哲）开始其职业生涯后，他曾是美国计算机科学公司的生命科学战略管理咨询部门CSC Healthcare的合伙人。Aurentz先生拥有维拉诺瓦大学数学学士学位，获得卓越奖章。
Vincent Aurentz has served as a member of Board of Directors since February 2025. Mr. Aurentz currently serves on the board of directors of Forward Therapeutics, Inc., a privately held biopharmaceutical company, since December 2024 and was a member of the board of directors of Longboard Pharmaceuticals, Inc., a then publicly traded clinical stage biopharmaceutical company, from October 2020 until its acquisition by Lundbeck A/S in December 2024. Previoly, he served as Executive Vice President and Chief Biness Officer at Arena Pharmaceuticals, Inc., a then publicly traded biopharmaceutical company, from Augt 2016 until its acquisition by Pfizer in March 2022. Mr. Aurentz was the Chief Biness Officer of Epir Biopharmaceuticals, Inc. and served as President and member of the board of directors of HemoShear Therapeutics, LLC. Prior to that, Mr. Aurentz spent almost a decade at Merck KGaA in vario executive leadership roles foced on corporate development and strategy including Executive Vice President and member of the Executive Management Board at Merck KGaA (Merck Serono S.A.) (XETR: MRK), where he directed all research and development programs, portfolio strategy and headed all deal activity including venture investments. Mr. Aurentz is a former Executive Vice President at Quintiles and a Co founder/Managing Director of a life sciences foced venture capital and advisory biness. He was a partner with CSC Healthcare, the life sciences strategic management consulting division of Computer Sciences Corporation, after starting his career at Andersen Consulting (now Accenture). Mr. Aurentz holds a B.S. in Mathematics, receiving the Medallion of Excellence, from Villanova University. - Vincent Aurentz自2025年2月起担任董事会成员。Aurentz先生目前自2024年12月起担任Forward Therapeutics，Inc.的董事会成员，Forward Therapeutics，Inc.是一家私营生物制药公司，并于2020年10月至2024年12月被Lundbeck A/S收购之前，曾是当时上市的临床阶段生物制药公司Longboard Pharmaceuticals, Inc.的董事会成员。Previoly，他于2016年8月在Arena Pharmaceuticals, Inc.担任执行副总裁兼首席BINCE官，该公司当时是一家上市的生物制药公司，直到2022年3月被辉瑞收购。Aurentz先生是Epir Biopharmaceuticals，Inc.的首席BINCE官，曾担任HemoShear Therapeutics，LLC的总裁和董事会成员。在此之前，Aurentz先生曾在默沙东 KGaA工作了近十年，担任过多个专注于企业发展和战略的行政领导职务，包括在默沙东 KGaA（默沙东 Serono S.A.）（XETR：MRK）担任执行副总裁兼执行管理委员会成员，在那里他指导了所有研发计划、投资组合战略并领导了包括风险投资在内的所有交易活动。Aurentz先生是昆泰公司的前执行副总裁，也是一家专注于生命科学的风险投资和咨询机构的联合创始人/董事总经理。在安德森咨询公司（现埃森哲）开始其职业生涯后，他曾是美国计算机科学公司的生命科学战略管理咨询部门CSC Healthcare的合伙人。Aurentz先生拥有维拉诺瓦大学数学学士学位，获得卓越奖章。
- Vincent Aurentz has served as a member of Board of Directors since February 2025. Mr. Aurentz currently serves on the board of directors of Forward Therapeutics, Inc., a privately held biopharmaceutical company, since December 2024 and was a member of the board of directors of Longboard Pharmaceuticals, Inc., a then publicly traded clinical stage biopharmaceutical company, from October 2020 until its acquisition by Lundbeck A/S in December 2024. Previoly, he served as Executive Vice President and Chief Biness Officer at Arena Pharmaceuticals, Inc., a then publicly traded biopharmaceutical company, from Augt 2016 until its acquisition by Pfizer in March 2022. Mr. Aurentz was the Chief Biness Officer of Epir Biopharmaceuticals, Inc. and served as President and member of the board of directors of HemoShear Therapeutics, LLC. Prior to that, Mr. Aurentz spent almost a decade at Merck KGaA in vario executive leadership roles foced on corporate development and strategy including Executive Vice President and member of the Executive Management Board at Merck KGaA (Merck Serono S.A.) (XETR: MRK), where he directed all research and development programs, portfolio strategy and headed all deal activity including venture investments. Mr. Aurentz is a former Executive Vice President at Quintiles and a Co founder/Managing Director of a life sciences foced venture capital and advisory biness. He was a partner with CSC Healthcare, the life sciences strategic management consulting division of Computer Sciences Corporation, after starting his career at Andersen Consulting (now Accenture). Mr. Aurentz holds a B.S. in Mathematics, receiving the Medallion of Excellence, from Villanova University.
高管简历
中英对照 | 中文 | 英文- Mark Iwicki
Mark Iwicki，自2015年9月起担任董事会主席。他曾担任Inhibikase Therapeutics， Inc.（制药公司）的首席执行官（2025年2月以来）。Iwicki先生从2015年9月到2025年2月担任首席执行官，从2017年8月到2021年12月担任总裁，从2015年4月到2015年9月担任董事会执行主席。加入公司之前，他曾担任Civitas Therapeutics， Inc. （Civitas，生物制药公司）的总裁兼首席执行官（2014年1月至2014年11月）。2012年12月至2014年1月，他担任Blend Therapeutics， Inc.（生物制药公司）的总裁兼首席执行官。加入Blend之前，Iwicki先生是Sunovion的总裁兼首席执行官。2007年10月至2012年6月，他在Sepracor Inc./Sunovion任职。加入Sepracor Inc.之前，他曾担任Novartis Pharmaceuticals Corporation（生物制药公司）的副总裁兼业务部门主管。1998年3月至2007年10月，他在诺华公司工作。在此之前，他在Astra Merck Inc.和Merck & Co., Inc.担任管理职务。除了担任Kala Bio， Inc.董事会成员外，他目前还担任Aerovate Therapeutics， Inc., Merus n.v。或Merus（公共临床阶段免疫肿瘤学公司），Akero Therapeutics, Inc., Third Harmonic Bio, Inc.和Q32 Bio Inc.的董事会成员，并曾担任immune Therapeutics， Inc.和Pulmatrix Inc.（所有上市公司）的董事会成员。他持有Ball State大学的工商管理学士学位和Loyola大学的工商管理硕士学位。
Mark Iwicki has served as a member of KALA BIO, Inc. board of directors since September 2015. Mr. Iwicki previoly served as KALA BIO, Inc. President from August 2017 to December 2021 and as Executive Chair of KALA BIO, Inc. board of directors from April 2015 to September 2015. Prior to joining KALA BIO, Inc., Mr. Iwicki served as President and Chief Executive Officer of Civitas Therapeutics, Inc., or Civitas, a biopharmaceutical company, from January 2014 to November 2014. Prior to Civitas, Mr. Iwicki served as President and Chief Executive Officer at Blend Therapeutics, Inc., or Blend, a biopharmaceutical company, from December 2012 to January 2014. Prior to Blend, Mr. Iwicki was President and Chief Executive Officer of Sunovion, a pharmaceutical company. Mr. Iwicki was at Sepracor Inc./Sunovion from October 2007 to June 2012. Prior to joining Sepracor Inc., Mr. Iwicki was Vice President and Biness Unit Head at Novartis Pharmaceuticals Corporation, a biopharmaceutical company. He was at Novartis from March 1998 to October 2007. Prior to that, Mr. Iwicki held management positions at Astra Merck Inc. and Merck & Co., Inc. In addition to serving on KALA BIO, Inc. board of directors, Mr. Iwicki also currently serves on the boards of Aerovate Therapeutics, Inc., Mer, Akero Therapeutics, Inc., Third Harmonic Bio, Inc. and Q32 Bio Inc. and formerly served on the board of Aimmune Therapeutics, Inc. and Pulmatrix Inc., all publicly traded companies. Mr. Iwicki holds a B.S. in Biness Administration from Ball State University and an M.B.A. from Loyola University.- Mark Iwicki，自2015年9月起担任董事会主席。他曾担任Inhibikase Therapeutics， Inc.（制药公司）的首席执行官（2025年2月以来）。Iwicki先生从2015年9月到2025年2月担任首席执行官，从2017年8月到2021年12月担任总裁，从2015年4月到2015年9月担任董事会执行主席。加入公司之前，他曾担任Civitas Therapeutics， Inc. （Civitas，生物制药公司）的总裁兼首席执行官（2014年1月至2014年11月）。2012年12月至2014年1月，他担任Blend Therapeutics， Inc.（生物制药公司）的总裁兼首席执行官。加入Blend之前，Iwicki先生是Sunovion的总裁兼首席执行官。2007年10月至2012年6月，他在Sepracor Inc./Sunovion任职。加入Sepracor Inc.之前，他曾担任Novartis Pharmaceuticals Corporation（生物制药公司）的副总裁兼业务部门主管。1998年3月至2007年10月，他在诺华公司工作。在此之前，他在Astra Merck Inc.和Merck & Co., Inc.担任管理职务。除了担任Kala Bio， Inc.董事会成员外，他目前还担任Aerovate Therapeutics， Inc., Merus n.v。或Merus（公共临床阶段免疫肿瘤学公司），Akero Therapeutics, Inc., Third Harmonic Bio, Inc.和Q32 Bio Inc.的董事会成员，并曾担任immune Therapeutics， Inc.和Pulmatrix Inc.（所有上市公司）的董事会成员。他持有Ball State大学的工商管理学士学位和Loyola大学的工商管理硕士学位。
- Mark Iwicki has served as a member of KALA BIO, Inc. board of directors since September 2015. Mr. Iwicki previoly served as KALA BIO, Inc. President from August 2017 to December 2021 and as Executive Chair of KALA BIO, Inc. board of directors from April 2015 to September 2015. Prior to joining KALA BIO, Inc., Mr. Iwicki served as President and Chief Executive Officer of Civitas Therapeutics, Inc., or Civitas, a biopharmaceutical company, from January 2014 to November 2014. Prior to Civitas, Mr. Iwicki served as President and Chief Executive Officer at Blend Therapeutics, Inc., or Blend, a biopharmaceutical company, from December 2012 to January 2014. Prior to Blend, Mr. Iwicki was President and Chief Executive Officer of Sunovion, a pharmaceutical company. Mr. Iwicki was at Sepracor Inc./Sunovion from October 2007 to June 2012. Prior to joining Sepracor Inc., Mr. Iwicki was Vice President and Biness Unit Head at Novartis Pharmaceuticals Corporation, a biopharmaceutical company. He was at Novartis from March 1998 to October 2007. Prior to that, Mr. Iwicki held management positions at Astra Merck Inc. and Merck & Co., Inc. In addition to serving on KALA BIO, Inc. board of directors, Mr. Iwicki also currently serves on the boards of Aerovate Therapeutics, Inc., Mer, Akero Therapeutics, Inc., Third Harmonic Bio, Inc. and Q32 Bio Inc. and formerly served on the board of Aimmune Therapeutics, Inc. and Pulmatrix Inc., all publicly traded companies. Mr. Iwicki holds a B.S. in Biness Administration from Ball State University and an M.B.A. from Loyola University.
- David McIntyre
David McIntyre自2025年4月起担任首席财务官职务。在加入之前，McIntyre先生分别于2021年10月至2024年10月、2020年10月至2021年10月、2019年11月至2020年11月担任临床阶段生物制药公司Anthos Therapeutics，Inc.、细胞治疗生物技术公司Tessa Therapeutics，Inc.和再生医学公司AVITA Medical Medical，Inc.（纳斯达克股票代码：RCEL）的首席财务官。在此之前，McIntyre先生曾于2012年12月至2020年4月担任生命科学风险投资和成长股权基金Apple Tree Partners的合伙人。在加入Apple Tree Partners之前，McIntyre先生是HeartWare的执行副总裁、首席财务官和首席运营官International，Inc.在其职业生涯的早期，McIntyre先生曾在Baker McKenzie和毕马威会计师事务所担任高级律师。McIntyre先生目前在生物制药公司Starpharma Holdings Limited（ASX：SPL）的董事会任职，previoly在Redflex Holdings Ltd.（ASX：RDF）担任董事。McIntyre先生拥有亚特兰大悉尼大学经济学（会计学）学士学位、亚特兰大悉尼科技大学法学学士学位和杜克大学Fuqua Biness学院（Fuqua Scholar）Biness Administration（MBA）硕士学位。McIntyre先生是一名注册执业会计师，还被接纳为新南威尔士州最高法委员会和亚特兰大高等法委员会的法律从业人员。
David McIntyre has served as Chief Financial Officer since April 2025. Prior to joining , Mr. McIntyre served as Chief Financial Officer of Anthos Therapeutics, Inc., a clinical stage biopharmaceutical company, Tessa Therapeutics, Inc., a cell therapy biotechnology company, and AVITA Medical, Inc. (NASDAQ: RCEL), a regenerative medicine company, from October 2021 to October 2024, October 2020 to October 2021, November 2019 to November 2020, respectively. Prior to that, Mr. McIntyre served as a Partner at Apple Tree Partners, a life science venture capital and growth equity fund from December 2012 to April 2020. Prior to Apple Tree Partners, Mr. McIntyre was Executive Vice President, Chief Financial Officer and Chief Operating Officer at HeartWare International, Inc. Earlier in his career, Mr. McIntyre practiced as a senior attorney at Baker McKenzie and KPMG. Mr. McIntyre currently serves on the board of directors of Starpharma Holdings Limited (ASX: SPL), a biopharmaceutical company, and previoly served as a director of Redflex Holdings Ltd. (ASX: RDF). Mr. McIntyre holds a Bachelor of Economics (Accounting) from the University of Sydney, Atralia, a Bachelor of Laws from the University of Technology, Sydney, Atralia and a Master of Biness Administration (MBA) from Duke University Fuqua School of Biness (Fuqua Scholar). Mr. McIntyre is a Certified Practicing Accountant and is also admitted as a legal practitioner of the Supreme Ct of New South Wales and of the High Ct of Atralia.- David McIntyre自2025年4月起担任首席财务官职务。在加入之前，McIntyre先生分别于2021年10月至2024年10月、2020年10月至2021年10月、2019年11月至2020年11月担任临床阶段生物制药公司Anthos Therapeutics，Inc.、细胞治疗生物技术公司Tessa Therapeutics，Inc.和再生医学公司AVITA Medical Medical，Inc.（纳斯达克股票代码：RCEL）的首席财务官。在此之前，McIntyre先生曾于2012年12月至2020年4月担任生命科学风险投资和成长股权基金Apple Tree Partners的合伙人。在加入Apple Tree Partners之前，McIntyre先生是HeartWare的执行副总裁、首席财务官和首席运营官International，Inc.在其职业生涯的早期，McIntyre先生曾在Baker McKenzie和毕马威会计师事务所担任高级律师。McIntyre先生目前在生物制药公司Starpharma Holdings Limited（ASX：SPL）的董事会任职，previoly在Redflex Holdings Ltd.（ASX：RDF）担任董事。McIntyre先生拥有亚特兰大悉尼大学经济学（会计学）学士学位、亚特兰大悉尼科技大学法学学士学位和杜克大学Fuqua Biness学院（Fuqua Scholar）Biness Administration（MBA）硕士学位。McIntyre先生是一名注册执业会计师，还被接纳为新南威尔士州最高法委员会和亚特兰大高等法委员会的法律从业人员。
- David McIntyre has served as Chief Financial Officer since April 2025. Prior to joining , Mr. McIntyre served as Chief Financial Officer of Anthos Therapeutics, Inc., a clinical stage biopharmaceutical company, Tessa Therapeutics, Inc., a cell therapy biotechnology company, and AVITA Medical, Inc. (NASDAQ: RCEL), a regenerative medicine company, from October 2021 to October 2024, October 2020 to October 2021, November 2019 to November 2020, respectively. Prior to that, Mr. McIntyre served as a Partner at Apple Tree Partners, a life science venture capital and growth equity fund from December 2012 to April 2020. Prior to Apple Tree Partners, Mr. McIntyre was Executive Vice President, Chief Financial Officer and Chief Operating Officer at HeartWare International, Inc. Earlier in his career, Mr. McIntyre practiced as a senior attorney at Baker McKenzie and KPMG. Mr. McIntyre currently serves on the board of directors of Starpharma Holdings Limited (ASX: SPL), a biopharmaceutical company, and previoly served as a director of Redflex Holdings Ltd. (ASX: RDF). Mr. McIntyre holds a Bachelor of Economics (Accounting) from the University of Sydney, Atralia, a Bachelor of Laws from the University of Technology, Sydney, Atralia and a Master of Biness Administration (MBA) from Duke University Fuqua School of Biness (Fuqua Scholar). Mr. McIntyre is a Certified Practicing Accountant and is also admitted as a legal practitioner of the Supreme Ct of New South Wales and of the High Ct of Atralia.
- Chris Cabell
Chris Cabell自2025年2月起担任总裁兼研发主管。在此之前，Cabell博士曾担任CorHepta Pharmaceuticals，Inc.的首席执行官，该公司是一家生物技术公司，该公司已被Inhibikase收购。Previoly，他于2023年1月至2024年1月在临床阶段生物制药公司Zura Bio担任首席医疗官，并于2021年2月至2023年1月在公共卫生公司Emergent BioSolutions担任首席医疗官和临床开发主管。在此之前，他曾于2017年10月至2020年11月在阿里那制药工作了3年，这是一家当时上市的生物制药公司，职责越来越重，包括高级副总裁、临床开发主管、首席医疗官和执行副总裁、研发主管。Cabell博士的职业生涯始于杜克大学医学院医学系心脏病学部的医学副教授。Cabell博士是美国心脏病学会的研究员，拥有超过100篇同行审查的出版物，包括在新英格兰医学期刊、JAMA和内科医学年鉴中。卡贝尔博士在内科和心血管疾病领域都获得了Board认证，他是宾夕法尼亚州立大学和杜克大学的荣誉毕业生，并从后者获得了医学博士和医学硕士学位。
Chris Cabell has served as President and Head of Research and Development since February 2025. Prior to this, Dr. Cabell served as Chief Executive Officer of CorHepta Pharmaceuticals, Inc., a biotechnology company, which was acquired by Inhibikase. Previoly, he served as Chief Medical Officer at Zura Bio, a clinical stage biopharmaceutical company, from January 2023 to January 2024, and as Chief Medical Officer and Head of Clinical Development at Emergent BioSolutions, a public health company, from February 2021 to January 2023. Prior to that, he spent 3 years at Arena Pharmaceuticals, a then publicly traded biopharmaceutical company with increasing responsibilities, including Senior Vice President, Head of Clinical Development, Chief Medical Officer and Executive Vice President, Head of Research and Development, from October 2017 to November 2020. Dr. Cabell started his career as an Associate Professor of Medicine in the Division of Cardiology, Department of Medicine, Duke University School of Medicine. Dr. Cabell is a Fellow of the American College of Cardiology and has over 100 peer revied publications including in the New England Jnal of Medicine, JAMA, and Annals of Internal Medicine. Board certified in both internal medicine and cardiovascular diseases, Dr. Cabell is an honors graduate of Pennsylvania State University and Duke University, earning both his M.D. and M.H.S. from the latter.- Chris Cabell自2025年2月起担任总裁兼研发主管。在此之前，Cabell博士曾担任CorHepta Pharmaceuticals，Inc.的首席执行官，该公司是一家生物技术公司，该公司已被Inhibikase收购。Previoly，他于2023年1月至2024年1月在临床阶段生物制药公司Zura Bio担任首席医疗官，并于2021年2月至2023年1月在公共卫生公司Emergent BioSolutions担任首席医疗官和临床开发主管。在此之前，他曾于2017年10月至2020年11月在阿里那制药工作了3年，这是一家当时上市的生物制药公司，职责越来越重，包括高级副总裁、临床开发主管、首席医疗官和执行副总裁、研发主管。Cabell博士的职业生涯始于杜克大学医学院医学系心脏病学部的医学副教授。Cabell博士是美国心脏病学会的研究员，拥有超过100篇同行审查的出版物，包括在新英格兰医学期刊、JAMA和内科医学年鉴中。卡贝尔博士在内科和心血管疾病领域都获得了Board认证，他是宾夕法尼亚州立大学和杜克大学的荣誉毕业生，并从后者获得了医学博士和医学硕士学位。
- Chris Cabell has served as President and Head of Research and Development since February 2025. Prior to this, Dr. Cabell served as Chief Executive Officer of CorHepta Pharmaceuticals, Inc., a biotechnology company, which was acquired by Inhibikase. Previoly, he served as Chief Medical Officer at Zura Bio, a clinical stage biopharmaceutical company, from January 2023 to January 2024, and as Chief Medical Officer and Head of Clinical Development at Emergent BioSolutions, a public health company, from February 2021 to January 2023. Prior to that, he spent 3 years at Arena Pharmaceuticals, a then publicly traded biopharmaceutical company with increasing responsibilities, including Senior Vice President, Head of Clinical Development, Chief Medical Officer and Executive Vice President, Head of Research and Development, from October 2017 to November 2020. Dr. Cabell started his career as an Associate Professor of Medicine in the Division of Cardiology, Department of Medicine, Duke University School of Medicine. Dr. Cabell is a Fellow of the American College of Cardiology and has over 100 peer revied publications including in the New England Jnal of Medicine, JAMA, and Annals of Internal Medicine. Board certified in both internal medicine and cardiovascular diseases, Dr. Cabell is an honors graduate of Pennsylvania State University and Duke University, earning both his M.D. and M.H.S. from the latter.
- David McIntyre
David McIntyre，2005年2月以来 ，他担任我们首席财务官和公司秘书。2008年他担任首席运营官职务。从2003年11月到2005年2月，他曾是Unilife Medical Solutions Limited的首席财务官和总法律顾问。他曾是Baker & McKenzie和KPMG Legal的私人开业高级律师，从事于企业、并购和资本市场。他也担任跨国公司的高级财务报告职务，包括Coal & Allied Limited（澳洲证券交易所（ASX）上市公司力拓集团（Rio Tinto group）的子公司）。他获得澳大利亚悉尼大学（ the University of Sydney）的会计方向经济学学士学位以及澳大利亚悉尼的悉尼科技大学（the University of Technology）的法学学士学位。他是注册会计师和澳大利亚新南威尔士州最高法院（the Supreme Court of New South Wales ）承认的法律从业者。他还是新南威尔士州的律师协会（the Law Society of New South Wales）的成员。
David McIntyre was appointed Chief Financial Officer in November 2019. Mr. McIntyre has more than 20 years of executive experience having held senior financial, legal and operational roles across multinational and growth-stage entities. Most recently, Mr. McIntyre served as a Partner with Apple Tree Partners ATP, a multibillion-dollar venture capture and growth equity fund focused exclusively on life sciences. At ATP, Mr. McIntyre was responsible for the medical device portfolio, together with various operating and board functions, including acting as Executive Vice President, Chief Financial Officer and Head of Technical Operations at Braeburn, Inc. Prior to ATP, Mr. McIntyre was Executive Vice President, Chief Financial Officer and Chief Operating Officer at HeartWare International, Inc. (previously ASX:HIN; NASDAQ: HTWR) where he oversaw HeartWare's financial, supply chain and operating functions as it transitioned from pre-clinical stage through commercialization across more than 20 countries. Prior to HeartWare, Mr. McIntyre practiced as a senior attorney in private practice specializing in corporate, mergers and acquisitions and equity capital markets with Baker & McKenzie and KPMG as well as holding various senior financial roles in multi-national companies, including within the Rio Tinto Group of companies. Mr. McIntyre holds a Bachelor of Economics (Accounting) from the University of Sydney (Australia), a Bachelor of Law from the University of Technology, Sydney (Australia) and a Master of Business Administration (Fuqua Scholar) from Duke University. He is also a Certified Practicing Accountant (CPA) and is admitted as a Legal Practitioner of the Supreme Court of New South Wales (in Australia).- David McIntyre，2005年2月以来 ，他担任我们首席财务官和公司秘书。2008年他担任首席运营官职务。从2003年11月到2005年2月，他曾是Unilife Medical Solutions Limited的首席财务官和总法律顾问。他曾是Baker & McKenzie和KPMG Legal的私人开业高级律师，从事于企业、并购和资本市场。他也担任跨国公司的高级财务报告职务，包括Coal & Allied Limited（澳洲证券交易所（ASX）上市公司力拓集团（Rio Tinto group）的子公司）。他获得澳大利亚悉尼大学（ the University of Sydney）的会计方向经济学学士学位以及澳大利亚悉尼的悉尼科技大学（the University of Technology）的法学学士学位。他是注册会计师和澳大利亚新南威尔士州最高法院（the Supreme Court of New South Wales ）承认的法律从业者。他还是新南威尔士州的律师协会（the Law Society of New South Wales）的成员。
- David McIntyre was appointed Chief Financial Officer in November 2019. Mr. McIntyre has more than 20 years of executive experience having held senior financial, legal and operational roles across multinational and growth-stage entities. Most recently, Mr. McIntyre served as a Partner with Apple Tree Partners ATP, a multibillion-dollar venture capture and growth equity fund focused exclusively on life sciences. At ATP, Mr. McIntyre was responsible for the medical device portfolio, together with various operating and board functions, including acting as Executive Vice President, Chief Financial Officer and Head of Technical Operations at Braeburn, Inc. Prior to ATP, Mr. McIntyre was Executive Vice President, Chief Financial Officer and Chief Operating Officer at HeartWare International, Inc. (previously ASX:HIN; NASDAQ: HTWR) where he oversaw HeartWare's financial, supply chain and operating functions as it transitioned from pre-clinical stage through commercialization across more than 20 countries. Prior to HeartWare, Mr. McIntyre practiced as a senior attorney in private practice specializing in corporate, mergers and acquisitions and equity capital markets with Baker & McKenzie and KPMG as well as holding various senior financial roles in multi-national companies, including within the Rio Tinto Group of companies. Mr. McIntyre holds a Bachelor of Economics (Accounting) from the University of Sydney (Australia), a Bachelor of Law from the University of Technology, Sydney (Australia) and a Master of Business Administration (Fuqua Scholar) from Duke University. He is also a Certified Practicing Accountant (CPA) and is admitted as a Legal Practitioner of the Supreme Court of New South Wales (in Australia).